share_log

和誉-B附属于2024 AACR展示3项临床前研究成果

Wayu-B is affiliated with 2024 AACR to present 3 preclinical research results

新浪港股 ·  Apr 9 19:27

Wayu-B (02256) announced that the company's subsidiary Shanghai Heyu Biomedical Technology Co., Ltd. (Heyu Pharmaceutical) announced that it presented the latest pre-clinical combination drug research results of its self-developed high-selective small molecule FGFR4 inhibitor irpagratinib (irpagratinib) in the form of an oral report at the 2024 American Association for Cancer Research (AACR) annual meeting. In addition, Heyu Pharmaceutical also published the latest pre-clinical research data on the self-developed innovative CSF-1R inhibitor pimicotinib (pimicotinib) and oral small molecule PD-L1 inhibitors in the form of posters.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment